Alzheimer’s

#Alzheimer's #Drug discovery #Genetics #Life sciences #Neuroscience #Therapeutics

Is new thinking the key to unlocking Alzheimer’s treatment?

Professor Paul Whiting, Chief Scientific Officer of The Alzheimer’s Research UK UCL Drug Discovery Institute (ARUK UCL DDI), and Stephane Martinez, product manager and neuroscience expert in PerkinElmer’s Life Sciences segment, share expert insights on Alzheimer’s Disease research today and where discovery and therapeutic approaches might be headed next. Read More

#Editor's Choice #News #Opinion

Seed funding
#Alzheimer's #Clinical trials #Drug discovery #Funding

€9 million to address ‘Agitation/Aggression’ in Alzheimer’s

Exciva has closed a Series A financing of €9 million, led by Andera Partners, to develop the lead compound up to completion of Phase I. The product has the potential to treat behavioral and psychological symptoms in Alzheimer disease patients. This compound is the combination of two clinically validated products,… Read More

#News

#Alzheimer's #Biotechnology #Covid-19 #Research

How has the pandemic impacted Alzheimer’s research? 

Sara Imarisio, Head of Strategic Initiatives at Alzheimer’s Research UK, reveals what dementia research could deliver and how Alzheimer’s research can help us re-imagine a future in which lives are saved.  Alzheimer’s and other forms of dementia have been impacted by Covid-19. With many labs forced to close… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Alzheimer's #Cancer research #Covid-19

This week in drug discovery (4-8 October) 

News round-up by DDW’s Megan Thomas for 4-8 October  For this week’s drug discovery round up, DDW’s Megan Thomas focuses on stories that provide answers to previously unanswered questions, or news that enables researchers and scientists to find those answers quickly.  1. Novel therapy could… Read More

#News #Trending News

#Alzheimer's #Clinical trials #Drug candidates #Drug discovery

First patients dosed in Phase I study for Alzheimer’s

AlzeCure Pharma has dosed the first patient in the company’s next clinical Phase I study (multiple ascending dose, MAD) with the candidate drug ACD856, focused on Alzheimer’s disease. ”It is satisfying that the clinical development program is proceeding according to plan and that we have now begun this follow-up Phase… Read More

#News #Trending News

#Alzheimer's

World Alzheimer’s Day 2021: Round up 

The last year has seen virology take the forefront of the drug discovery sector as experts collaborated and worked with unprecedented speed to develop a Covid-19 vaccine to reach an end to the global coronavirus pandemic. But other industries have continued to work tirelessly to develop treatments for other… Read More

#News #Trending News

#Alzheimer's #Brain disease #Drug targets #Schizophrenia

Research reveals drug targets for memory enhancement  

Bristol-led research has identified specific drug targets within the neural circuits that encode memories, paving the way for significant advances in the treatment of a broad spectrum of brain disorders.  Loss of memory is a core feature of many neurological and psychiatric disorders including Alzheimer’s disease and… Read More

#News

#Alzheimer's #Drug development #Funding #Research

NIH awards $15 million for Alzheimer’s research

The National Institute of Aging (NIA), part of the National Institutes of Health, has awarded Wake Forest School of Medicine $15.2 million over five years in support of its research centre for Alzheimer’s disease. Established in 2016 with a multimillion-dollar NIA grant, the Alzheimer’s Disease Research Center (ADRC) at Wake… Read More

#News #Trending News

#Alzheimer's #Drug development #Pharma #Research

New data supports targeting Trk receptors for treating Alzheimer’s

AlzeCure Pharma’s presentation and poster regarding the clinical candidate drug ACD856 for Alzheimer’s disease, presented at the Alzheimer’s Association International Conference (AAIC) 2021 on July 26-30 in Denver, USA, are now available on its website. The abstract, ACD856 – a novel positive allosteric modulator of Trk-signaling in clinical development for… Read More

#News

#Alzheimer's #Data #Drug delivery #Drug design #Exscientia #Pharma

The role of AI in Alzheimer’s drug candidate design

Last month, the AI-driven pharma-tech company, Exscientia announced that the world’s first Alzheimer’s disease (AD) drug candidate designed by artificial intelligence (AI) was entering Phase I clinical trials. This is the result of a collaboration with DSP, a Japanese pharmaceutical company. The drug candidate is being assessed for antipsychotic effects… Read More

#Exclusive Content #News

#Alzheimer's #Drug development #Drug discovery #FDA #Research

Historic breakthrough in the treatment of Alzheimer’s

The US Food and Drug Administration (FDA) has approved Biogen’s regulatory application for the use of aducanumab in the treatment of Alzheimer’s disease, which removes amyloid from brains. Aducanumab is the first new Alzheimer’s drug in nearly 20 years, and there is reportedly mixed evidence over its efficacy. However, according… Read More

#News

#Alzheimer's #Clinical trial #Drug development #Drug discovery #Drug targets #Immuno-oncology

Can this clinical trial move us closer to an Alzheimer’s treatment?

Exscientia has announced a Phase I clinical study of DSP-0038 in the US for the treatment of Alzheimer’s disease psychosis. DSP-0038 is the third molecule created using Exscientia’s Artificial Intelligence (AI) technologies to enter clinical trials. The two earlier compounds are DSP-1181, announced in 2020 together with Sumitomo Dainippon Pharma… Read More

#News

#Alzheimer's #Biologics

C. elegans: a natural model for developing therapies to slow ageing

Ageing is a complex and heterogeneous process and is best studied using natural models of ageing in whole organisms and large test populations. C. elegans is a proven model in many fields of biology including ageing, where major breakthroughs have occurred by identifying mutants and interventions that increase… Read More

#News #Videos

#Alzheimer's #Biotechnology #Biotherapeutics #Clinical trials #Drug development #Therapeutics

Clinical Ink adds 16th concurrent Alzheimer’s study

Clinical Ink, a clinical trial technology company, has announced the addition of its 16th concurrent Phase II/III Alzheimer’s disease study, exemplifying its ongoing commitment to this therapeutic area. Clinical Ink’s platform supports the needs of sponsors working on Alzheimer’s trials by using direct collection tools that allow for flexible data… Read More

#News

#Alzheimer's #Dementia #Drug development #Drug discovery

Researchers discover critical step in formation of fatal brain diseases

A research team from Imperial College London and the University of Zurich have identified what causes normal proteins to convert to diseased form, causing conditions like Creutzfeldt-Jakob disease (CJD) and Kuru. The researchers also tested a way to block the process, which could lead to new drugs for combatting such… Read More

#News

#AI / data analytics / healthtech / informatics #Alzheimer's #Biomarkers #iLoF

The start-up that knows one size doesn’t fit all

Luis Valente, CEO & Co-Founder of iLoF, has been recognized by Forbes as one of the top 30 under 30 for science and healthcare. He told Lu Rahman what’s behind his start-up that recently secured $1 million in investment from Microsoft’s Venture Fund, M12 and Mayfield Fund and won the… Read More

#Start-up Zone